Chief Development Officer

Niclas Brynne

Niclas Brynne, born in 1961, holds a Doctorate in medical sciences, clinical pharmacology and a M.Sc. in biochemistry. Brynne has more than 30 years of experience in pre-clinical and clinical drug development in senior positions within Pharmacia Corp. and AstraZeneca. He was part of the group that developed Detrusitol for Pharmacia and led a large number of clinical drug development programs, translational medicine and worked with licensing at AstraZeneca. Niclas has also led the development of diagnostics for MentisCura Diagnostics and sat on the board of the Stockholm Brain Institute.